ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/anti-ERBB2-monoclonal-antibody-dimerization-inhibitor
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/anti-ERBB2-monoclonal-antibody-dimerization-inhibitor
4
trial(s) found.
NCT05593094
Advanced
Phase 1
Recruiting
A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ZN-A-1041 Enteric Capsules as a Single Agent or in Combination in Patients With HER2-Positive Advanced Solid Tumors (
ZN-A-1041-101-US
)
ERBB2 inhibitor
+ anti-ERBB2 monoclonal antibody,dimerization inhibitor
HER2-positive breast cancer
Solid tumour
VIC
3021 - St Albans - Western Health - Sunshine Hospital
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05150691
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2a, Multicenter, Open-Label, First in Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of DB-1303/BNT323 in Patients With Advanced/Metastatic Solid Tumors (
DB-1303-O-1001
)
anti-ERBB2 antibody-drug conjugate
+ anti-ERBB2 monoclonal antibody,dimerization inhibitor
HER2-positive solid tumour
NSW
2031 - Randwick - Scientia Clinical Research Ltd
2109 - North Ryde - Macquarie University Hospital
VIC
3168 - Clayton - Monash Medical Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
NCT04802759
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER) (
CO42867
)
AKT inhibitor
Abemaciclib
Atezolizumab
CDK4/6 inhibitor
CDK4 inhibitor
CDK6 inhibitor
CDK7 inhibitor
Everolimus
Giredestrant
Inavolisib
Ipatasertib
PI3K alpha inhibitor
Palbociclib
Pertuzumab
Ribociclib
Samuraciclib
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
anti-PD-L1 monoclonal antibody
cancer therapy
cancer therapy,AKT-targeting
cancer therapy,CDK4-targeting
cancer therapy,CDK6-targeting
cancer therapy,CDK7-targeting
cancer therapy,ERBB2-targeting
cancer therapy,ESR1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PI3Kalpha-targeting
cancer therapy,mTOR-targeting
cancer therapy,mTORC1-targeting
endocrine therapy
endocrine therapy,oestrogen axis-targeting
immune checkpoint blockade
immune checkpoint blockade,PD-L1-targeting
immuno-oncology therapy,ERBB2-targeting
immuno-oncology therapy,PD-L1-targeting
mTORC1 inhibitor
mTOR inhibitor
oestrogen receptor-targeting therapy
pan-AKT inhibitor
selective estrogen receptor degrader
+ anti-ERBB2 monoclonal antibody,dimerization inhibitor
Breast cancer
ER-positive breast cancer
VIC
3000 - Melbourne - Peter MacCallum Cancer Centre
3199 - Frankston - Peninsula Health Frankston Hospital
SA
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Linear Clinical Research
ACTRN12622000016730
Advanced
Phase 1
Recruiting
Addition of prochlorperazine to paclitaxel, trastuzumab, and pertuzumab for previously untreated HER2-positive metastatic breast cancer: a phase 1 dose de-escalation study (
HER2Pro-1B
)
anti-ERBB2 monoclonal antibody
anti-ERBB2 monoclonal antibody,dimerization inhibitor
antihistamine
taxane
HER2-positive breast cancer
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4102 - Woolloongabba - Princess Alexandra Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (4)
Recruitment Country and State
VIC (3)
NSW (2)
QLD (2)
NZ (1)
SA (1)
WA (1)
Phase
Phase 1 (2)
Phase 1 / Phase 2 (2)
Trial Type
Advanced (4)
Cancer Therapy Class
ERBB2
100%
SMO
25%
AKT
25%
CDK4
25%
CDK6
25%
CDK7
25%
ER
25%
PD-1/PD-L1
25%
PD-L1
25%
PI3Kalpha
25%
mTOR
25%
mTORC1
25%
oestrogen axis
25%
Facility
3021 - St Albans - Western Health - Sunshine Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (1)
2031 - Randwick - Scientia Clinical Research Ltd (1)
2109 - North Ryde - Macquarie University Hospital (1)
3168 - Clayton - Monash Medical Centre (1)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (1)
3000 - Melbourne - Peter MacCallum Cancer Centre (1)
3199 - Frankston - Peninsula Health Frankston Hospital (1)
5042 - Bedford Park - Flinders Medical Centre (1)
6009 - Nedlands - Linear Clinical Research (1)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
Cancer Type
Cancer
Solid tumour
Breast adenocarcinoma
Breast cancer
HER2-positive breast cancer
HER2-positive solid tumour
ER-positive breast cancer
HR-positive breast cancer
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy